Skip to content
Screener

Monte Rosa Therapeutics, Inc. GLUE Q2 2026 earnings

Reported August 6, 2026 · Before market open

Revenue$9.0MMiss by $3.9M
EPS-$0.43Miss by $0.05
Revenue estimate$12.9M
EPS estimate-$0.38
“Importantly, for our VAV1 program, Novartis recently activated a Phase 2 study evaluating MRT-6160 (DDY391) in individuals with Sjögren's disease, representing an important step forward for this program and established collaboration. We look forward to additional Phase 2 study activations expected as part of a broader development effort to evaluate the potential of MRT-6160 across other immune-mediated diseases. In addition, the Phase 2 study of MRT-2359 in combination with apalutamide in mCRPC patients with AR mutations is now activated, and we expect to enroll our first patients imminently, positioning us to validate the strong signals of clinical activity we observed in this patient population in our Phase 1/2 trial. We will update data from the initial Phase 1/2 arm exploring MRT-2359 in advanced CRPC by the end of the year.”
Markus Warmuth

Next report

Nov 5, 2026 (in a month)
Revenue estimate$31.5M
EPS estimate-$0.24

Financials

Q2 2026

Income statement

See full
Revenue$9.0M-61.3%
Operating income-$49.1M-216%
Net income-$43.4M-253%
EPS (diluted)-$0.43-187%

Balance sheet

See full
Cash & equivalents$90.1M+29.8%
Total debt$38.0M-7.6%
Total equity$487.3M+81.8%
Total assets$691.2M+92.2%

Cash flow

See full
Operating cash flow-$44.1M-27.1%
CapEx$4.7M+179%
Free cash flow-$48.8M-34.1%

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$960.63M+104%
Enterprise value$908.51M+200%
P/S33.4×+30.8×

Profitability

See full
Operating margin-633%—
Net margin-560.8%—
FCF margin-111.7%-125pp

Returns & leverage

See full
Return on equity-42.7%—
Debt / equity0.1×-0.1×
Current ratio10.6×+3.4×

FAQ

When did Monte Rosa Therapeutics, Inc. report Q2 2026 earnings?
Monte Rosa Therapeutics, Inc. (GLUE) reported Q2 2026 earnings on August 6, 2026 before market open.
What were Monte Rosa Therapeutics, Inc.'s Q2 2026 revenue and EPS?
Monte Rosa Therapeutics, Inc. reported revenue of $9.0M and eps of $-0.43 for Q2 2026.
Did Monte Rosa Therapeutics, Inc. beat estimates in Q2 2026?
Revenue missed the consensus estimate of $12.9M by $3.9M. EPS missed the consensus estimate of $-0.38 by $0.05.
How did Monte Rosa Therapeutics, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 61.2% from $23.2M a year earlier and eps declined 186.7% from $-0.15.
Where can I find Monte Rosa Therapeutics, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-336681) and the 10-Q periodic report (0001193125-26-336711) directly on SEC EDGAR. The filing index links above go to sec.gov.